TIUM.U Stock Overview Through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cansortium Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cansortium Historical stock prices Current Share Price US$0.075 52 Week High US$0.28 52 Week Low US$0.065 Beta 3.02 1 Month Change 0% 3 Month Change -58.33% 1 Year Change -46.43% 3 Year Change -87.70% 5 Year Change -80.26% Change since IPO -96.15%
Recent News & Updates
Cansortium Inc. Announces the Launch of Bag-O Jan 07
Slammed 29% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch Dec 27
Cansortium Inc. (CNSX:TIUM.U) completed the acquisition of RIV Capital Inc. (CNSX:RIV) from JW Asset Management, LLC and others. Dec 20
Cansortium Inc. Announces FLUENT Becomes First-To-Market Dispensary in Florida to Offer Freedom Town Holdings’ New Flower Window Bags Dec 18
Now 27% undervalued after recent price drop Dec 03
Cansortium Inc. Expands Popular MOODS Vaporizer Line with Premium Offerings in New York and Florida Dec 03 See more updates
Cansortium Inc. Announces the Launch of Bag-O Jan 07
Slammed 29% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch Dec 27
Cansortium Inc. (CNSX:TIUM.U) completed the acquisition of RIV Capital Inc. (CNSX:RIV) from JW Asset Management, LLC and others. Dec 20
Cansortium Inc. Announces FLUENT Becomes First-To-Market Dispensary in Florida to Offer Freedom Town Holdings’ New Flower Window Bags Dec 18
Now 27% undervalued after recent price drop Dec 03
Cansortium Inc. Expands Popular MOODS Vaporizer Line with Premium Offerings in New York and Florida Dec 03
Third quarter 2024 earnings released: US$0.039 loss per share (vs US$0.018 loss in 3Q 2023) Dec 01
Cansortium Inc. Announces the Launch of Hyer Kind Nov 21
Cansortium Inc. (CSE:TIUM.U) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny Nov 07
Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt Oct 25
New minor risk - Shareholder dilution Sep 10
Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward Sep 04
Second quarter 2024 earnings released: EPS: US$0.003 (vs US$0.018 loss in 2Q 2023) Aug 23
Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment Aug 21
Cansortium Inc. to Report Q2, 2024 Results on Aug 22, 2024 Aug 16
CEO & Director exercised options to buy US$58k worth of stock. Jul 11
Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch Jul 11
Cansortium Inc., Annual General Meeting, Aug 27, 2024 Jun 20
First quarter 2024 earnings released: US$0.014 loss per share (vs US$0.027 loss in 1Q 2023) Jun 04 Cansortium Inc. (CNSX:TIUM.U) entered into a definitive arrangement agreement to acquire RIV Capital Inc. (CNSX:RIV) for $26.28 million. May 31
Cansortium Inc. Announces Chief Financial Officer Changes May 18
Full year 2023 earnings released: US$0.078 loss per share (vs US$0.15 loss in FY 2022) Apr 30
Cansortium Inc. to Report Q4, 2023 Results on Apr 29, 2024 Apr 28
Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story Jan 15
Third quarter 2023 earnings released: US$0.009 loss per share (vs US$0.022 loss in 3Q 2022) Nov 30
Is Cansortium (CSE:TIUM.U) Using Too Much Debt? Nov 30
Cansortium Inc. to Report Q3, 2023 Results on Nov 29, 2023 Nov 11
Cansortium Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 07
Is Cansortium (CSE:TIUM.U) Using Debt Sensibly? Sep 01
Second quarter 2023 earnings released: US$0.018 loss per share (vs US$0.014 loss in 2Q 2022) Aug 30
Cansortium Inc. to Report Q2, 2023 Results on Aug 28, 2023 Aug 22
New major risk - Share price stability Aug 13
Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough Jul 28
Less than half of directors are independent Jul 25
Cansortium Inc. Announces Board Changes Jul 23
First quarter 2023 earnings released: US$0.027 loss per share (vs US$0.04 loss in 1Q 2022) Jun 01
Cansortium Inc., Annual General Meeting, Jul 26, 2023 May 27
Cansortium Inc. Announces the Launch of Its New Cannabis-Infused Dark Chocolate Bar in Florida May 25
Cansortium Inc. to Report Q1, 2023 Results on May 31, 2023 May 24
Full year 2022 earnings: EPS misses analyst expectations May 03
An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued Mar 08
Now 28% undervalued after recent price drop Mar 07
Now 23% undervalued after recent price drop Feb 17
Now 21% undervalued after recent price drop Feb 01
Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet? Jan 09
Price target decreased to US$0.83 Jan 06
No longer forecast to breakeven Jan 06
Cansortium Inc. Revises Earnings Guidance for the Year 2022 Nov 30
Cansortium Inc. to Report Q3, 2022 Results on Nov 29, 2022 Nov 24
Cansortium Inc. Appoints Liora Boudin as Interim CFO Nov 22
Cansortium Inc. Announces Resignation of Patricia Fonseca as Chief Financial Officer, Effective November 21, 2022 Oct 12 Cansortium Inc. Provides Business Update Following Hurricane Ian Oct 07
Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden Sep 09
Second quarter 2022 earnings released: US$0.014 loss per share (vs US$0.11 loss in 2Q 2021) Aug 30
Cansortium Inc. Provides Earnings Guidance for the Year 2022 Aug 30
Cansortium Inc. to Report Q2, 2022 Results on Aug 29, 2022 Aug 24
First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.026 loss in 1Q 2021) Jun 16
Cansortium Inc. Reaffirms Earnings Guidance for the Year 2022 Jun 01
Cansortium Inc. Provides Revenue Guidance for the Year 2022 May 05
No longer forecast to breakeven Apr 27
High number of new and inexperienced directors Apr 27
Cansortium Inc. announced that it has received $2.5 million in funding Dec 08
Price target decreased to US$1.48 Dec 03
No longer forecast to breakeven Dec 03
Third quarter 2021 earnings: Revenues miss analyst expectations Dec 02
Cansortium Inc. Receives Approval from Florida Department of Health to Commence Operation Aug 26
Second quarter 2021 earnings released Aug 25
Cansortium Inc. Revises Revenue Guidance for the Year 2021 Aug 25
Independent Director David Abrams has left the company Jul 13
Independent Chairman Neal Hochberg has left the company Jul 13
First quarter 2021 earnings released May 31
Cansortium Inc. Reiterates Financial Guidance for 2021 May 29
Cansortium Inc. Provides Consolidated Financial Outlook for 2021 May 04
Cansortium Inc. announced that it has received $17.2 million in funding Apr 11
Cansortium Inc. announced that it expects to receive $12 million in funding Apr 06
New 90-day high: US$0.82 Mar 16
Analysts update estimates Feb 17 Cansortium Inc. Announces Executive Changes
New 90-day high: US$0.81 Feb 11
Cansortium Inc. announced that it has received $0.674218 million in funding Feb 10
Cansortium Inc. Announces Board Changes Jan 22
New 90-day high: US$0.77 Jan 08
New 90-day high: US$0.52 Dec 24
Cansortium Inc. Announces Executive Changes Dec 23
New 90-day high: US$0.46 Dec 04
Revenue beats expectations, earnings disappoint Nov 25
New 90-day high: US$0.39 Nov 07
Cansortium Inc. Commences Edibles Sales in Florida Following Receipt of Regulatory Approval Oct 15
New 90-day low: US$0.29 Oct 06
Cansortium Inc. Appoints Robert Beasley as Chief Executive Officer Sep 30
Price target lowered to US$0.83 Sep 19 Cansortium Inc. announced that it has received $2.082102 million in funding Sep 01
Shareholder Returns TIUM.U CA Pharmaceuticals CA Market 7D 0% 0.9% 2.6% 1Y -46.4% -42.8% 17.7%
See full shareholder returns
Return vs Market: TIUM.U underperformed the Canadian Market which returned 17.7% over the past year.
Price Volatility Is TIUM.U's price volatile compared to industry and market? TIUM.U volatility TIUM.U Average Weekly Movement 23.0% Pharmaceuticals Industry Average Movement 12.9% Market Average Movement 8.3% 10% most volatile stocks in CA Market 18.5% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: TIUM.U's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: TIUM.U's weekly volatility has increased from 17% to 23% over the past year.
About the Company Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. The company’s medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles under the Fluent brand name. It also sells various third-party branded medical cannabis products.
Show more Cansortium Inc. Fundamentals Summary How do Cansortium's earnings and revenue compare to its market cap? TIUM.U fundamental statistics Market cap US$24.06m Earnings (TTM ) -US$19.71m Revenue (TTM ) US$104.19m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TIUM.U income statement (TTM ) Revenue US$104.19m Cost of Revenue US$44.07m Gross Profit US$60.12m Other Expenses US$79.83m Earnings -US$19.71m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.066 Gross Margin 57.70% Net Profit Margin -18.92% Debt/Equity Ratio -1,240.1%
How did TIUM.U perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 00:32 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cansortium Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Russell Stanley Beacon Securities Limited Jonathan DeCourcey BTIG Robert Burleson Canaccord Genuity
Show 2 more analysts 
